Table 4

LOAEL symptoms of the DBPCFC-positive children
Patient Age (months) Sex Amount of CMP (mg) Symptoms
Acute reactions
29 7,5 F ? ery
30 134 M ? os, nau
35 115 M 18 sw
63 4 M 18 ery
108 42,5 F 18 os, vom, sw
34 10 M 180 ery
90 26 F 360 ery, ur
42 14,5 M 540 ur
93 3 M 540 col
6 3,5 M 720 ery
107 7 M 720 cry, vom
14 5,5 M 1080 ery, ur
85 5 M 1080 dia
104 119 M 1080 ap, nau
47 11 M 1620 ery, vom, dysp, whe
54 8,5 F 1620 vom
59 7,5 M 1620 ery
66 24 F 1620 ery
87 7 F 1620 ec
95 6 M 1620 cry, dia
114 11 F 1620 dia, ery, cry, agi
121 17 M 1620 ery, ur
123 4 F 1620 agi, fp
Late reactions
9 7,5 F 1620 dia, cry
19 12,5 M 1620 sp, ery
21 6 M 1620 ec, con
27 5,5 M 1620 dysp
32 5,5 M 1620 ec, cry
37 2,5 F 1620 agi
39 5 F 1620 cry
62 13 F 1620 col, cry, con
65 7 F 1620 con
73 7 M 1620 agi, cry, dia
76 15,5 F 1620 cry, sp
79 7,5 F 1620 vom, cry
86 5 F 1620 dia
103 4 M 1620 agi
111 4,5 F 1620 con

DBPCFC, double-blinded placebo-controlled food challenge; LOAEL, lowest observed adverse effect level; agi, agitation; ap, abdominal pain; col, colic; con, constipation; cry, crying; dia, diarrhea; dysp, dyspnea; ec, worsening eczema; ery, erythema; fp, feeding problems; itch, itching; nau, nausea; os, oropharyngeal symptoms; sw, swelling; ur, urticaria; vom, vomiting; whe, wheezing; sp, sleeping problems. Amounts of 18, 180, 360, 540, 720, 1080 and 1620 mg CMP correspond with 1, 10, 20, 30, 40, 60 and 90 ml test feeding respectively.

Dambacher et al.

Dambacher et al. Nutrition Journal 2013 12:22   doi:10.1186/1475-2891-12-22

Open Data